Conventional roller- or blade-based powder application methods limit the versatility of powder-based additive manufacturing technologies such as Laser Powder Bed Fusion (PBF-LB). In particular, the restricted multi-material capabilities, the strong dependence on powder flowability and the need to fill the entire build platform with powder are major drawbacks of conventional powder application. Electrophotographic powder application (EPA) has emerged as a promising new technology to overcome these limitations. It utilizes electrostatic interaction forces to selectively attract and repel charged powder particles. This publication demonstrates the potential of EPA-PBF-LB for pharmaceutical 3D printing and applications in medical engineering. Using EPA, tablets containing different active pharmaceutical ingredients (APIs) have for the first time been successfully printed with a CO₂ laser without thermal degradation of the APIs. This is an important step towards personalized medicine. It has also been shown that EPA-PBF-LB can be used to precisely functionalize surfaces to provide bactericidal properties. For this purpose, silver-nanocoated polyamide 12 (Ag-PA12) was selectively deposited and consolidated using EPA-PBF-LB. In this way, it was possible to locally achieve bactericidal properties. This can be of great interest for applications in the field of medical engineering or even in everyday life, e.g. on surfaces in public transport or hospitals.